At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers are assessing maintenance therapy with olaparib given for 1 or 2 years, with or without bevacizumab, to treat ovarian cancer. The people in this study have stage 3 or 4 ovarian cancer with certain genetic mutations (changes).
-
Researchers are comparing mosunetuzumab to the usual treatment (rituximab) for nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). They want to see if one drug is more effective than the other to shrink the cancer with a long-lasting response.
-
Researchers in this study want to see how a new form of radiation therapy works to treat metastatic cancer. Metastatic means the cancer has spread to another part of the body from its original place. The people in this study have solid tumors that spread to soft tissues in the chest, abdomen (belly), or pelvis. In addition, they need radiation therapy to help control symptoms such as pain.
-
There is not an accepted or usual approach to treat patients 75 years of age or older diagnosed with diffuse large B-cell lymphoma (DLBCL). Doctors are seeking effective but less intensive treatment regimens, with fewer side effects, for these patients. A standard treatment for DLBCL is R-CHOP (a combination of the drugs rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
-
The purpose of this study is to find the highest dose of the investigational drug CA-4948 that can be given safely and to evaluate its preliminary anticancer effectiveness in patients with non-Hodgkin lymphoma that has come back or continued to grow despite prior therapy. CA-4948 works by blocking a protein in normal and cancerous B cells (a type of immune cell) called IRAK4, which may promote the growth and survival of B cells in lymphoma. CA-4948 is designed to fight cancer by blocking IRAK4, thereby stopping or reducing the signals that promote lymphoma B-cell survival.
- A Phase II Study of Photobiomodulation Therapy in Children and Adults with Oral Graft-versus-Host Disease after Stem Cell Transplantation
Full Title A Multi-center, Phase II, Randomized Double-blind Trial to Evaluate the Efficacy and Safety of PhotobiomoduLatIon for the Treatment of Oral Chronic Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation (The LIGHT Trial)
Purpose
The purpose of this study is to assess the safety and effectiveness of a specialized light treatment for children and adults with chronic graft-versus host disease (GVHD) of the mouth (oral GVHD) that has not improved after standard treatment. GVHD is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient’s body and cause serious health problems. Oral GVHD can cause mouth inflammation, pain, and sores.
The light treatment in this study is called photobiomodulation (PBM) therapy. PBM uses a device with red and near infrared light to help wounds heal, decrease inflammation, and reduce pain on the parts of the body where it is applied.
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants must have chronic GVHD of the mouth that is not getting better despite standard treatment.
- This study is for people age 4 and older.
Contact
For more information and to ask about eligibility for this study, please contact the office of Dr. Alina Markova at 646-608-2342.
Protocol
22-271Phase
Phase II (phase 2)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05675930ClinicalTrials.gov
-
Pirtobrutinib works by blocking a protein called BTK, which helps cancer cells grow and survive. By blocking this protein, pirtobrutinib may help stop cancer cells from growing and spreading. It is taken orally (by mouth).
-
BG-60366 is designed to break down the mutated EGFR protein, which promotes the growth of NSCLC. BG-60366 is taken orally (by mouth).
-
In this study, researchers want to find the best dose of ABBV-319 to use in people with B-cell cancers. The people in this study have B-cell cancers that keep growing even after treatment. Examples of B-cell cancers treated in this study include:
-
Researchers want to find the best dose of AZD0305 to use in people with multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing after treatment. AZD0305 is given intravenously (by vein).